Literature DB >> 23279927

Derivative (5;19)(p10;q10): a rare but recurrent whole-arm translocation in acute myeloid leukemia.

Masahiro Manabe1, Teruhito Takakuwa, Hirofumi Nakano, Naonori Harada, Shuichiro Okamoto, Yasutaka Aoyama, Takeo Kumura, Tadanobu Ohta, Yoshio Furukawa, Mitsuhiro Matsuda, Atsuko Mugitani.   

Abstract

A previous study of cases of myelodysplastic syndrome harboring der(5;19)(p10;q10) found that they displayed common characteristics including predominance in elderly men, dysplasia involving three hematopoietic lineages and CD7 expression in blasts. However, the whole-arm translocation der(5;19)(p10;q10) has not been fully analyzed because of its rarity. In this study we used flow cytometry to evaluate the immunophenotype of two patients' bone marrow mononuclear cells. Both patients had involved der(5;19)(p10;q10) in their karyotype analyzed by standard G-banding technique. Both patients had the CD7+ and CD41+ phenotype, and the CD41 positivity suggested that the myeloid neoplasms involving der(5;19)(p10;q10) were of megakaryoblastic origin. The der(5;19)(p10;q10) abnormality is associated with unique characteristics of the immunophenotype. We address the clinical, immunophenotypic and morphological aspects of hematological malignancy involving der(5;19)(p10;q10), along with a review of the literature.
© 2012 Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  CD41; acute myeloid leukemia; der(5;19)(p10;q10); megakaryoblast; whole-arm translocation

Mesh:

Year:  2012        PMID: 23279927     DOI: 10.1111/ajco.12051

Source DB:  PubMed          Journal:  Asia Pac J Clin Oncol        ISSN: 1743-7555            Impact factor:   2.601


  1 in total

Review 1.  5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).

Authors:  Hiroshi Ureshino; Haruna Kizuka; Kana Kusaba; Haruhiko Sano; Atsujiro Nishioka; Takero Shindo; Yasushi Kubota; Toshihiko Ando; Kensuke Kojima; Shinya Kimura
Journal:  Int J Hematol       Date:  2016-12-02       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.